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Background: Caspase-8 inhibits necrosis by 
regulating RIP1 and RIP3. 
Results: Caspase-8 knockdown T-cells 
simultaneously underwent apoptosis and 
nonapoptotic cell death. 
Conclusion: Procaspase-8 prevents T-cells from 
multiple types of RIP1/3-dependent cell death. 
Significance: RIP1/3 can regulate 
caspase-3-dependent apoptosis as well as 
non-apoptotic cell death. 
 
SUMMARY 
Caspase-8 has an important role as an 
initiator caspase during death receptor- 
mediated apoptosis. Moreover, it has been 
reported to contribute to the regulation of cell 
fate in various types of cells including T-cells. 
In this paper, we show that caspase-8 has an 
essential role in cell survival in mouse 
T-lymphoma-derived L5178Y cells. The 
knockdown of caspase-8 expression decreased 
the growth rate and increased cell death, both 
of which were induced by the absence of 
protease activity of procaspase-8. The cell 
death was associated with reactive oxygen 
species (ROS) accumulation, caspase 
activation and autophagosome formation. 
The cell death was inhibited completely by 
treatment with ROS scavengers, but only 
partly by treatment with caspase inhibitors, 
expression of Bcl-xL, and knockdown of 
caspase-3 or Atg-7 which completely inhibits 
apoptosis or autophagosome formation, 
respectively, indicating that apoptosis and 
autophagy-associated cell death are induced 
simultaneously by the knockdown of 
caspase-8 expression. Further analysis 
indicated that RIP1 and RIP3 regulate this 
multiple cell death, because the cell death as 
well as ROS production was completely 
inhibited by not only treatment with the RIP1 
inhibitor necrostatin-1, but also by 
knockdown of RIP3. Thus, in the absence of 
protease activity of procaspase-8, RIP1 and 
RIP3 simultaneously induce not only 
nonapoptotic cell death conceivably including 
autophagic cell death and necroptosis but also 
apoptosis through ROS production in mouse 
T-lymphoma cells. 
 
Apoptosis has important physiological roles 
in embryonic development, immune regulation 
and the maintenance of homeostasis in adult 
tissues. Caspases, members of the cysteine 
protease family, are essential to the induction of 
apoptosis (1,2). Two major pathways of 
apoptosis are known; a mitochondrial pathway 
(intrinsic pathway) and a death receptor pathway 
(extrinsic pathway) (3). Both require the 
activation of a variety of caspases. Moreover, 
caspases are known to be pro-enzymes which 
become activated by cleavage at aspartate 
residues upon death signaling (4).  
Caspase-8 was originally identified as an 
initiator caspase and mainly functions in the 
death receptor pathway of apoptosis. Upon 
ligation of a death receptor such as Fas, 
caspase-8 is recruited to a complex known as a 
death-inducing signaling complex (DISC) 
together with other factors including the Fas- 
associated death domain (FADD) (5,6). Within 
the complex, caspase-8 becomes catalytically 
activated by undergoing proximity-induced 
auto-cleavage through homo-oligomerization. 
The activated caspase-8 conveys the death signal 
to downstream factors mainly to executor 
caspases including caspase-3 and 7, which then 
cleave various cellular proteins to complete the 
apoptosis-inducing process (7,8). 




in apoptosis, some findings imply a 
non-apoptotic function. In mice, the knockout of 
caspase-8 caused embryonic death at 10.5 to 12 
days with an associated deficiency in heart 
development, neural tube formation and 
angiogenesis (9,10). This has been also observed 
in knockout of FADD, a death-domain 
containing adaptor protein, and of 
cellular-FLICE-like inhibitory protein (c-FLIP), 
a catalytically inactive caspase-8 homolog 
(11,12). Therefore, the components of DISC are 
essential to embryonic development. 
In the immune system, apoptosis is important 
for lymphocyte development and homeostasis 
such as the elimination of auto-reactive T- and 
B-cells and activated T-cells after their initial 
expansion (13-15). In mice, however, 
conditional caspase-8 knockout in T-cells caused 
decrease in numbers of mature T-cells in 
pancreas and lymph gland, and the 
caspase-8-deficient T-cells were highly defective 
in clonal expansion upon mitogenic stimulation 
(11,16-19). Furthermore, in T-cell-derived cell 
lines, a decrease and an increase in the number 
of proliferating and dying cells, respectively, 
were reported to be induced by treatment with 
z-VAD-fmk, a pan-caspase inhibitor (20-22). 
Since z-VAD-fmk inhibits the protease activity 
of pan-caspases, the protease activity of 
caspases may have another essential function in 
cell survival. Despite many reports indicating a 
crucial non-apoptotic function of caspase-8 in 
T-cell development, the precise mechanism by 
which caspase-8 regulates the clonal expansion 
or survival of T-cells is unclear.  
A loss of caspase-8 was reported to result in 
the accumulation of reactive oxygen species 
(ROS), which induces non-apoptotic cell death 
or caspase-independent cell death such as 
autophagic cell death or necrotic cell death also 
known as necroptosis (23,24). Necroptosis is 
initiated by receptor-interacting 
serine/threonine-protein kinase (RIP) 1 and 
RIP3 in response to the activation of death 
receptors, and can be blocked by a RIP1 
inhibitor, necrostatin-1 (Nec-1) (25). The most 
recent works showed that caspase-8 constantly 
inhibits necroptosis, an alternative programmed 
cell death pathway, by regulating RIP1 and RIP3 
during embryonic development and T-cell 
expansion (26,27). Also, RIP1 deficiency was 
found to restore the viability of FADD-null 
T-cells (28). It is highly likely that caspase-8 and 
FADD regulate cell fate in embryogenesis by 
regulating RIP1- and RIP3-dependent 
necroptosis. 
In this study, the significance of the 
non-apoptotic function of caspase-8 and its 
mechanism were explored. We confirmed that 
cell death was induced in a mouse 
lymphoma-derived T-cell line, L5178Y, by the 
knockdown of caspase-8 expression. The 
caspase-8 knockdown cells showed apoptosis 
and non-apoptotic cell death including 
autophagic cell death, both of which were 
simultaneously induced by the accumulation of 
ROS. Moreover, the cell death was completely 
reversed by treatment with Nec-1 or by 
knockdown of RIP3 expression. It is suggested 
that protease activity of procaspase-8 in 
T-lymphoma cells inhibits RIP1 and/or RIP3, 
which triggers cells multiple types of cell death 





Cell lines – The mouse leukemic lymphoblast 
cell line L5178Y was maintained in a suspension 
culture in RPMI 1640 medium (Nacalai Tesque 
Inc.) supplemented with 5% fetal bovine serum 
(Sigma), 100 U/ml penicillin, 100 μg/ml 
streptomycin (Nacalai Tesque Inc.), and 50 μM 
β-mercaptoethanol (Sigma), at 37˚C in 5% CO . 
Human embryonic kidney-derived 293T cells, 
and Balb/C wild type and Caspase-8-/- mouse 
embryonic fibroblasts obtained in our laboratory 
were cultured in Dulbecco’s modified Eagle’s 
medium (Nacalai Tesque Inc.) supplemented 
with 10% fetal bovine serum (Sigma), 100 U/ml 
penicillin, and 100 μg/ml streptomycin (Nacalai 
Tesque Inc.).  
 
Plasmids - The expression vector for wild-type 
caspase-8 was sub-cloned from the vector as 
described before (29). A protease inactive form 
of caspase-8 (CS mutant) (See Fig. 2A) was 
constructed with the primer, 
5’-ATTCAGGCTAGCCAAGGAAGT-3’ (for 
C362S). A mutant without 7 putative cleavage 
sites (DE mutant) (See Fig. 2A) was constructed 
with 5’-GAGGAGATGAGCCT CAAAAT-3’ 
(for D201E), 
5’-CTGTGTGAGTCGCCAAGAGAACAAGA
GAGTGAGTCA-3’ (for D212E and D218E), 
5’-GGAGT GCCTGAGGAGGCAGG-3’ (for 
D373E), 5’-AAGTGGAGTCATCATCTCAC-3’ 
(for D387E), and 
5’-GAGGAGGCAGAGTTTCTGCT-3’ (for 
D397E and D400E). Mouse caspase-8 with 
silent mutations in the target nucleotides of 
shRNA for caspase-8 (WT*) was constructed 
with the primer, 
5’-CGGGAAGAAATGGTGAGGGAG-3’ 
(encoding R83-E89), and the CS and DE 
mutants were constructed as substituents of 
WT* mouse caspase-8 with a flag-tag. Human 
Bcl-xL cDNA was amplified by RT-PCR from 
cDNA of Jurkat cells. All constructs generated 
by PCR were verified by DNA sequencing. For 
expression of LC3, the original plasmid, 
pEGFP-C1-LC3, was kindly provided by T. 
Yoshimori (Osaka University, Japan). 
EGFP-conjugated LC3 cDNA was sub-cloned 
and inserted into a lentiviral expression vector, 





Lentiviral expression vectors - Lentiviral vectors, 
provided by H. Miyoshi (RIKEN, Japan), were 
prepared as described earlier (30). For the 
expression of the WT*, CS mutant, and DE 
mutant of caspase-8, cDNA fragments were 
inserted into both CSII-PGK-MCS-IRES-EGFP 
and CSII-PGK-3xFLAG-MCS-IRES-puro. For 
Bcl-xL expression, cDNA was inserted into both 
CSII-PGK-3xFLAG-MCS-IRES-puro and CSII- 
EF-MCS-IRES-puro.  
 
shRNA expression system - To achieve the 
specific knockdown of caspase-8, the 
tetracycline-inducible short hairpin RNA 
(shRNA) expression system (Tet-On shRNA 
system) with lentivirus-based vectors was 
utilized as described previously (31). shRNA 
expression was induced by the treatment of cells 
with 10 ng/ml doxycyclin (Dox) (Nacalai 
Tesque Inc.). The oligonucleotides of shRNA for 
mouse caspase-8 (shCasp-8) were generated 
from nucleotides 248 to 266 of caspase-8 cDNA 
(GeneBank no. NM_009812.2). The 
oligonucleotides of shRNA for silencing lacZ 
(32), and for silencing ATG7 (23) were 
previously described. For the specific 
knockdown of RIP3, shRNA for mouse RIP3 
was generated from nucleotides 413 to 431 of 
RIP3 cDNA (GeneBank no NM_019955.2). 
shRNA for mouse caspase-3 was generated from 
nucleotide 762 to 780 of caspase-3 cDNA 
(GeneBank no NM_009810). 
 
Detection of cell death – The percentage of cells 
undergoing cell death was quantified by trypan 
blue exclusion method using a hemocytometer 
after the addition of an equal amount of 0.4% 
trypan blue solution in PBS to the suspended 
culture. Cell death was also quantified by lactate 
dehydrogenase (LDH) release method; the 
integrity of the cell membrane was measured by 
quantifying the amount of LDH released from 
dead cells using the CytoTox-ONE 
Homogeneous Membrane Integrity Assay 
(Promega) as described (31). Results obtained 
by trypan blue exclusion method were 
essentially same as those by LDL release 
method. The DNA ladder assay was performed 
as described (33). To quantify apoptotic cells, 
cells were stained with propidium iodide (PI) 
and percentage of sub-diploid (sub-G1) cells 
was measured by flow cytometric analysis as 
previously described (30). Apoptotic cells were 
also examined by analyzing nuclear morphology 
of cells stained with DAPI as described 
previously (31). 
 
Reagents –Inhibitors used in this study were 
z-VAD-fmk (PEPTIDE INSTITUTE, INC.), 
z-IETD-fmk (R&D Systems), z-DEVD-fmk 
(R&D Systems), z-LEHD-fmk (R&D Systems), 
wortmanin (Santa Cruz), and Necrostatin-1 
(Nec-1) (Santa Cruz). Butylated hydroxyanisole 
(BHA) (Sigma) was used as a ROS scavenger. 
tert-butylhydro-peroxide (Sigma) was used as a 
ROS inducer.  
 
Western blot analysis and antibodies - Cells 
were lysed in ice-cold lysis buffer (20 mM 
Tris-HCl, pH7.4 with 10% glycerol, 1% Triton 
X-100, 0.5% NP-40, 150 mM NaCl, and 1 mM 
EDTA) containing a protease inhibitor cocktail 
(Roche Molecular Biochemicals). Cell lysates 
were resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and then analyzed by Western 
blotting as described previously (34). The 
antibodies used for detection were 
anti-caspase-8 (1:1000; 1G12; Alexis 
Biochemicals), anti-caspase-3 (1:1000; Cell 
Signaling), anti-caspase-9 (1:500; Cell 
Signaling), anti-PARP (1:1000; Cell Signaling), 
anti-Bcl-xL (1:1000; Cell Signaling), anti-RIP3 
(1:1000; Enzo Life Sciences), anti-Flag (1:2000; 
M2; Sigma), anti-GFP (1:1000; 1E4; MBL), and 
anti-actin (1:5000; Chemicon). 
 
qRT-PCR - Total RNA was isolated with a 
RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. The reverse 
transcription (RT) reaction was carried out with 
8-20 ng of total RNA using a SuperScript III 
Platinum SYBR Green One-Step qRT-PCR Kit 
(Invitrogen) according to the manufacturer’s 
instructions. RT products were analyzed with an 
ABI PRISM 7500 (Applied Biosystems). The 
level of each mRNA was normalized to that of 
GAPDH, and expressed as a ratio to the level in 
control shRNA (shRNA for LacZ: 
shLacZ)-expressing cells. 
 
Detection of Reactive Oxygen Species (ROS) - 
Cells were washed with PBS twice and then 
exposed for 15 min at 37oC to 160 μM 
hydroethidine (DHE) dissolved in PBS. 
Analyses were performed on an EPICS XL flow 
cytometer (Beckman Coulter). The data were 




Caspase-8 is essential for cell survival in 
L5178Y cells - To examine the role of caspase-8 
in T-cell survival, we first treated mouse 
T-lymphoma-derived L5178Y cells with 
z-VAD-fmk, a pan-caspase inhibitor which 
blocks protease activities of various caspases 
including caspase-8, and quantified the cell 
death by trypan blue exclusion method. We 
found that L5178Y cells treated with 
z-VAD-fmk showed a decrease in cell growth 
and an increase in cell death (Fig. 1A and B). 
Also, we performed the same experiment with a 
caspase-8-specific inhibitor, z-IETD-fmk, and 




cell death (Supplemental Fig. 1A). These results 
suggested that the cell death induced by 
z-VAD-fmk is caused by the inhibition of 
caspase-8 activity. 
To further investigate the function of 
caspase-8 in T-cells, gene-specific 
downregulation of caspase-8 expression was 
performed by utilizing the previously 
established Tet-On shRNA expression system 
with lentivirus-based expression vectors (31). In 
L5178Y cells expressing Tet-On shCasp-8, 
caspase-8 expression started to be 
down-regulated at the protein level after 24 h of 
Dox treatment (Fig. 1C). We observed a reduced 
cell proliferation rate and an increased rate of 
cell death specifically in the caspase-8 
knockdown cells (Fig. 1D and E). It was 
confirmed that caspase-8 has an essential role in 
cell survival in L5178Y cells. 
 
Protease activity but not auto-cleavage activity 
of procaspase-8 is required for cell survival  - 
Caspase-8 knockdown by induced expression of 
shCasp-8 provoked cell death in mouse L5178Y 
cells. We further examined whether cell survival 
can be recovered by expression of exogenous 
mouse caspase-8 with silent mutations in the 
target nucleotides of shCasp-8 (WT*). In 
addition, we constructed two caspase-8 mutants; 
CS and DE, which hold a Cys to Ser mutation in 
the protease domain (C362S) and 7 Asp to Glu 
mutations in expected cleavage sites of 
caspase-8 itself and other caspases, respectively, 
as substituents of WT* mouse caspase-8 with a 
flag tag (Fig. 2A). These CS and DE mutants 
were expressed in caspase-8 knockout mouse 
embryonic fibroblasts by utilizing lentivirus 
expression vectors. By treatment of the cells 
with agonistic anti-Fas antibody, we confirmed 
that the CS and DE mutants did not undergo 
auto-cleavage since cleaved forms of caspase-8 
were not detected upon the apoptosis-inducing 
stimulation (Fig. 2B).  
To find out whether the protease activity 
and/or cleavage-associated activation of 
caspase-8 are necessary for cell survival in 
L5178Y cells, we exogenously expressed either 
WT*, CS or DE mutant in Tet-On 
shCasp-8-expressing cells and examined their 
levels (Fig. 2C). After the induction of shRNA 
expression by treatment with Dox, cell 
proliferation and cell death population were 
quantified (Fig. 2D and E). Expression of WT* 
caspase-8 enhanced cell proliferation and 
inhibited cell death in shCasp-8-expressing cells. 
DE mutant-expressing cells showed essentially 
the same rates of growth and cell death as 
WT*-expressing cells, indicating that activation 
of caspase-8 by auto-processing and cleavage by 
other caspases are not involved in cell survival. 
On the other hand, CS mutant-expressing cells 
showed essentially the same number of cells 
undergoing death as in the shCasp-8-expressing 
parental cells. Taken together, protease activity 
of procaspase-8 is indispensable for cell survival 
in L5178Y cells, but cleavage-associated 
activation of procaspase-8 is not necessary for 
cell survival. 
 
Caspase-8-deficient L5178Y cells undergo 
apoptosis - We next examined the type of cell 
death induced by the knockdown of caspase-8 in 
L5178Y cells. Although cell death among 
caspase-8-deficient cells was previously shown 
to be non-apoptotic (35) or necroptosis (36-38), 
we first explored the characteristics of apoptosis 
in the knocked down cells. Cleaved forms of 
caspase-3 and PARP, a substrate of caspase-3, as 
well as decreased levels of procaspase-9 were 
observed after 36 and 48 h treatment with Dox 
in Tet-On shCasp-8-expressing L5178Y cells 
(Fig. 3A). Moreover, a DNA ladder, another 
characteristic of apoptosis, was also observed in 
the caspase-8-deficient cells (Fig. 3B). Thus, 
apoptosis was induced in L5178Y cells by the 
knockdown of caspase-8 expression. 
To further determine whether apoptosis is the 
only type of cell death induced by knockdown of 
caspase-8, we at first blocked the protease 
activities of caspase-3 and -9 with z-DEVD-fmk 
and z-LETD-fmk, specific inhibitors for 
caspase-3/7 and caspase-9, respectively. These 
inhibitors could only partially inhibit the 
caspase-8 knockdown-induced cell death 
(Supplemental Fig. 1B and C). We then blocked 
the intrinsic pathway of apoptosis by 
over-expressing the anti-apoptotic protein 
Bcl-xL (Supplemental Fig. 2). The levels of the 
Bcl-xL expressed under the control of promoters 
for eEF1A1 or PGK, were much higher than the 
endogenous levels, and apoptosis induced by 
staurosporin was blocked in the established cells 
expressing Bcl-xL. Upon shCasp-8 expression, 
however, cell death in Bcl-xL-expressing cells 
was still induced; the number of dead cells was 
more than half of that in Bcl-xL-unexpressing 
cells. These results suggested that not only 
apoptosis but also other types of cell death might 
be induced by knockdown of caspase-8 
expression in L5178Y cells. 
 To make certain apoptosis and other types of 
cell death to be simultaneously induced in each 
of caspase-8 knockdown cells, we generated 
caspase-3 knockdown cells and closely analyzed 
cell death in these cells after induced 
knockdown of caspase-8. Expression of 
caspase-3 was effectively down-regulated by 
expression of shRNA specific for caspase-3 
(shCasp-3) in L5178Y cells with Tet-On 
shCasp-8 (Fig. 3C), and the caspase-3 
knockdown cells were resistant to 
staurosporin-induced apoptosis (data not shown). 
The cell growth retardation and cell death, 
quantified by trypan blue exclusion method, 
were not affected by the knockdown of 




was also quantified by LDH release method (Fig. 
3F), and the results obtained by the both 
methods were same. These results indicate that 
cell death population was not affected in 
caspase-3 knockdown cells. To exclude the 
possibility that apoptosis is still induced in part 
of the caspase-3 knockdown cells, we examined 
sub-G1 population and nuclear morphology on 
cell per cell basis. While knockdown of 
casepase-8 effectively increased the number of 
sub-G1 cells, knockdown of caspase-3 
expression, which could not inhibit the 
caspase-8 knockdown-induced cell death, 
clearly inhibits the generation of sub-G1 
population (Fig. 4A). Moreover, 
apoptosis-specific chromosomal fragmentation 
and chromosomal condensation near the nuclear 
periphery, both of which were induced by 
caspase-8 knockdown, were inhibited by 
caspase-3 knockdown (Fig. 4B). Interestingly, 
the size of nucleus of the caspase-3 knockdown 
cells was smaller than that of viable cells not 
treated with Dox, and the morphology of 
nucleus in caspase-3 knockdown cells was quite 
different from that of the viable cells. All the 
data suggest that caspase-8 knockdown 
simultaneously induces caspase-3-dependent 
apoptosis and other types of cell death in each of 
cells. 
 
Autophagy was also observed in caspase-8 
down-regulated L5178Y cells - We then 
examined the onset of autophagy in caspase-8 
knockdown cells. During the formation of 
autophagosomes, light chain associated protein 3 
(LC3) is transformed from LC3-I to LC3-II by 
lipidation, and this transformation is an indicator 
of autophagy (39). We detected this 
transformation in caspase-8 knockdown cells but 
not in control cells (Fig. 5A). Expression of 
ATG7, which is indispensable for the formation 
of autophagosomes, was down-regulated by 
expression of shRNA specific for ATG7 in 
caspase-8 knockdown L5178Y cells. Although 
the knockdown of ATG7 expression is partial 
(Fig. 5B), transformation of LC3 was attenuated 
by expression of shATG7 in caspase-8 
knockdown cells (Fig. 5A). Importantly, cell 
death induced by caspase-8 knockdown was 
partly reduced by the knockdown of ATG7 
expression (Fig. 5C). Taken together, autophagic 
cell death was also induced when the expression 
of procaspase-8 was down-regulated. To further 
confirm this, caspase-8 knockdown cells were 
treated with wortmanin, which was utilized as an 
inhibitor of autophagy. Upon treatment with 
wortmanin, both growth retardation and cell 
death were partially reduced in caspase-8 
knockdown cells (Fig. 5D and E). Taken 
together, not only apoptotic cell death but also 
autophagic cell death is induced in cells lacking 
procaspase-8 activity.  
 
Cell death in caspase-8 knockdown T-cells was 
mediated by ROS accumulation - We then 
analyzed whether ROS was accumulated in the 
caspase-8 knockdown cells. Firstly, we 
examined the effect of BHA, a ROS scavenger, 
on the cell death. Cell death in caspase-8 
knockdown cells was almost completely rescued 
by treatment with BHA (Fig. 6A and B). We 
then measured intracellular levels of ROS by 
using hydroethidine (DHE). ROS accumulation 
was detected in Tet-On shCasp-8-expressing 
L5178Y cells after 36 and 48 h treatment with 
Dox, and BHA treatment inhibited its 
accumulation (Fig. 6C). These results indicated 
that oxidative stress is the cause of apoptosis and 
autophagic cell death in caspase-8 knockdown 
L5178Y cells.  
 
 
RIP1 and RIP3 are key factors inducing cell 
death in caspase-8-deficient L5178Y cells - We 
next explored whether RIP1 and RIP3, which 
were reported to be involved in the induction of 
necroptosis in caspase-8-deficient cells, 
contribute to the cell death. We first examined 
the effect of Nec-1, a RIP1 inhibitor (25), on cell 
proliferation and viability in caspase-8 
knockdown L5178Y cells. The cell viability was 
almost completely restored by treatment with 
Nec-1 (Fig. 7A). We then examined the 
involvement of RIP3 in the cell death. The cell 
death induced in caspase-8 knockdown cells was 
almost completely prevented by expression of 
shRNA specific for RIP3 (Fig. 7B and C). In 
RIP3 and caspase-8 double-knockdown cells as 
well as Nec-1-treated caspase-8 knockdown 
cells, the accumulated ROS level was 
significantly decreased compared to that in 
caspase-8 single knockdown cells not treated 
with Nec-1 (Fig. 7D). All the results in this 
study clearly indicate that knockdown of 
caspase-8 simultaneously induces apoptosis and 
non-apoptotic cell death including autophagic 





Treatment with z-VAD-fmk, a pan-caspase 
inhibitor, was reported to induce cell death in 
some types of cells (20,22). Recently, evidence 
has emerged that the cell death could be caused 
by the absence of the non-apoptotic function of 
caspase-8 in T-cells (23). Here, we observed the 
induction of cell death in mouse T 
lymphoma-derived L5178Y cells not only by 
treatment with z-VAD-fmk but also by 
down-regulation of caspase-8 expression. A 
similar phenomenon has been reported in mouse 
fibroblast-derived L929 cells as well as primary 
T-cells derived from the conditional knockout 
mice of caspase-8 (16,17,23). These results 




function in cell survival in several types of cells. 
Meanwhile, we also analyzed the effects of 
caspase-3- or caspase-9-specific inhibitors, and 
down-regulation of caspase-3 expression; 
however, neither cell death nor delayed cell 
proliferation was observed in L5178Y cells. 
Therefore, the cell death induced by caspase 
inhibition should be specific to caspase-8.  
Even though we show here the importance of 
caspase-8 to prevent cell death in mouse 
T-lymphoma-derived L5178Y cells, caspase-8 
was originally found to function in death 
receptor-mediated apoptosis. Activation of 
procaspase-8 is prompted by auto-cleavage at 
Asp210, Asp216, Asp374, and Asp384 (in 
human) in DISC. After oligomerization within a 
DISC, procaspase-8 undergoes auto-cleavage, 
and then translocates into the cytosol as an 
activated dimer harboring the active pocket with 
the active site Cys283 (40,41). Procaspase-8 was 
also reported to be cleaved by caspase-6 
resulting in the formation of the active dimer, 
which process might function to form the 
positive feedback loop of caspase activation in 
induction of apoptosis (42,43). Our DE mutant 
does not retain the Asp residue in linker 
sequences where procaspase-8 is cleaved by 
caspase-8 itself and other caspases. Therefore, it 
would not be activated under any conditions, 
while previously reported DE mutants have the 
potential to be activated by other caspases. In 
fact, the exogenously expressed mouse DE 
mutant was confirmed never to be activated in 
human KB cells with endogenous caspase-8 
where apoptosis was induced through both 
intrinsic and extrinsic pathways (data not 
shown). The results of this study showed that the 
DE-mutant compensated for the function of 
WT* caspase-8, whereas the CS-mutant did not. 
Taken together, our data clearly showed that the 
activation of caspase-8 is not necessary for cell 
survival in L5178Y cells, but protease activity of 
procaspase-8 to cleave its target substrates is 
indispensable for cell survival. 
Whereas caspase-8 deficiency was reported to 
induce multiple types of cell death, such as 
autophagic cell death and necrosis (44,45), it is 
still controversial what type of cell death is 
actually induced as a result of the absence of 
procaspase-8 activity (20,24,45,46). In L929 
cells, caspase-8 deficiency was reported to 
induce degradation of a ROS scavenger protein, 
catalase, resulting in ROS accumulation and 
autophagic cell death (20,23). Other reports 
showed that FADD and caspase-8 form a 
feedback loop to limit autophagy, a pathway 
important for rapid T-cell proliferation (46). In 
mouse T-lymphoma- derived L5178Y cells, we 
indeed observed autophagy-dependent cell death, 
which was inhibited by expression of shATG7 
and by treatment with wortmanin, an inhibitor of 
autophagosome formation. In addition, 
caspase-8 and FADD were reported to form a 
salvage pathway from necroptosis dependent on 
RIP1 kinase (27,28). Recently, both RIP1 and 
RIP3 were reported to be involved in caspase-8- 
deficiency-induced embryonic lethality and cell 
death in caspase-8-deficient T-cells (26-28). 
According to those reports, it is likely that 
caspase-8 constantly suppresses necroptosis by 
inhibiting the activation of RIP1 and RIP3 not 
only in T-cells but also in other types of cells 
during embryonic development. Therefore, 
caspase-8-deficient cells must have the capacity 
to undergo necroptosis. In L5178Y cells, it was 
also observed that the cell death induced by 
caspase-8-deficiency was rescued by either 
treatment with a RIP1 inhibitor, Nec-1, or 
expression of shRIP3 (Fig. 7). These results 
indicate that RIP kinases are involved in the 
outcome of the events induced by caspase-8 
dysfunction, and necroptosis would occur in 
L5178Y cells. Furthermore, we clearly indicated 
that apoptosis is also induced by caspase-8 
deficiency in addition to previously reported 
autophagic cell death in mouse 
T-lymphoma-derived L5178Y cells. Taken 
together, protease activity of procaspase-8 
would inhibit various types of cell death 
including apoptosis, autophagic cell death and 
necroptosis, all of which are simultaneously 
induced in the absence of caspase-8. 
ROS accumulation was reported to be also 
observed in caspase-8 knockdown cells (23,46). 
Indeed, caspase-8 deficiency-induced cell death 
was completely rescued in caspase-8 
knockdown L5178Y cells by treatment with 
BHA, a ROS scavenger. Moreover, an elevation 
of intracellular ROS levels was observed in 
caspase-8 knockdown cells downstream of the 
activation of RIP1 and RIP3. Taken together, 
knockdown of caspase-8 simultaneously induces 
apoptosis, and other types of cell death through 
RIP1- and RIP3-mediated ROS accumulation. 
One of the plausible interpretations of multiple 
types of cell death induced in caspase-8 
knockdown L5178Y cells would be that 
apoptosis and autophagic cell death might be 
induced as secondary events of ROS 
accumulation along with necroptosis induced by 
activation of RIP1 and RIP3. Activated RIP1 
and RIP3 were reported to increase the energy 
metabolism which results in accumulation of 
ROS (47). Taken together, procaspase-8 might 
constantly regulates activation of RIP1 and/or 
RIP3 in L5178Y cells to protect cells from 
unusual energy metabolism, therefore, cells 
survive by maintaining intracellular ROS levels. 
Even though there still remain many unknown 
reasons why casapase-8 deficiency leads to cell 
death, our study clearly showed that the protease 
activity of procaspase-8 is essential for cell 
survival in L5178Y cells through inhibiting ROS 
accumulation induced by activation of RIP1 and 
RIP3. Since it is known that mutation of 




(18), further analysis of procaspase-8 function in 
T-cells may contribute better understanding of 
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FIGURE 1. Caspase-8 has an essential role in cell survival in L5178Y cells.  A and B. Cells were 
treated with z-VAD-fmk in DMSO or DMSO only for the periods indicated. z-VAD-fmk was added 
every 24 h. Numbers of viable and dead cells were quantified by trypan blue exclusion method using a 
hemocytometer. Total viable cell number (A) and % of dead cells (B) are indicated. Results obtained 
by trypan blue exclusion method were essentially same as those by LDL release assay. Results 
representative experiments carried out in triplicate are shown. (All error bars: ±S.D.) C. Tetracycline 
repressor (TetR)-expressing L5178Y cells were infected with lentiviral vectors with the Tet-On 
shRNA-expression system encoding shRNA specific for LacZ (shLacZ) or caspase-8 (shCasp-8). 
After induction of shRNA expression by treatment with 10 ng/ml Dox for the periods indicated, cell 
lysate was analyzed by Western blotting with anti-caspase-8 and anti-actin antibody. *: a non-specific 
band. D and E. After treatment with 10 ng/ml Dox for indicated periods, numbers of viable and dead 




FIGURE 2. Protease activity of procaspase-8 is necessary for the survival of L5178Y cells. A. 
Schematic view of caspase-8. Mutated sites for caspase-8 without protease activity (CS mutant) and 
without sites of cleavage by caspases including caspase-8 itself (DE mutant) are shown. B. 
Flag-tagged wild type, CS mutant and DE mutant of caspase-8 (casp-8) were expressed in mouse 
embryonic fibroblasts (MEFs) derived from caspase-8 knockout mice. Cells were treated with 100 
ng/ml anti-Fas antibody (Jo2) and 1μg/ml cycloheximide for 24 h, and then cleavage of caspase-8 was 
analyzed by Western blotting with anti-Flag antibody. *: nonspecific bands. C. Flag-tagged forms of 
caspase-8 (casp-8) were expressed in Tet-On shCasp-8-expressing L5178Y cells. Cells without Dox 
treatment were analyzed by Western blotting with anti-Flag, anti-caspase-8 (casp-8), and anti-actin 
antibodies. D and E. After treatment with 10 ng/ml Dox for the periods indicated, numbers of viable 
and dead cells were quantified as described in Fig. 1. Results representative of experiments carried out 
in triplicate were shown. (All error bars: ±S.D.) 
 
 
FIGURE 3. Down-regulated procaspase-8 activity resulted in apoptotic cell death. A. After 
induction of shLacZ or shCasp-8 expression by treatment with 10 ng/ml Dox for the indicated periods, 
cell lysate was analyzed by Western blotting with antibodies to caspase-3, caspase-9, PARP, and actin. 
B. Cleaved genomic DNA was extracted from cells expressing Tet-On shLacZ or shCasp-8 after 
treatment with 10 ng/ml Dox for the periods indicated, and resolved by agarose gel electrophoresis. 
C-F. L5178Y cells with Tet-On shCasp-8 were infected with a lentiviral expression vector encoding 
shRNA specific for caspase-3 (shCasp3) or shLacZ. Cell lysate was analyzed by Western blotting with 
anti-caspase-3 and anti-actin antibodies (C). After treatment with 10 ng/ml Dox for the periods 
indicated, numbers of viable and dead cells were quantified as described in Fig. 1 (D and E). 
Percentage of dead cells was also quantified by LDL release assay (F). Cell death [%] = (amount of 
LDH released in culture medium) / (amount of LDH released in culture medium plus that retained in 
viable attached cells) × 100. Results representative of experiments carried out in triplicate were shown. 
(All error bars: ±S.D.).  
 
 
FIGURE 4. Effects of casepase-3 knockdown on caspase-8 knockdown-induced cell death. A. 
Cells described in Figure 3C were cultured with or without 10 ng/ml Dox for 36 h. After staining with 
propidium iodide (PI), percentage of sub-diploid (sub-G1) cells was measured by flow cytometric 
analysis to quantify apoptotic cells. B. Cells, cultured with or without Dox for 48 h, were stained with 
DAPI and analyzed under a fluorescence microscope. Arrows and arrowheads indicate nuclei with 




FIGURE 5. Down-regulated procaspase-8 activity induces autophagy. A. GFP-fused LC3 was 
over-expressed in L5178Y cells with either Tet-On shLacZ, Tet-On shCasp-8, or Tet-On shCasp-8 and 
shATG7 vectors. After treatment with 10 ng/ml Dox for the periods indicated, cell lysate was analyzed 
by Western blotting with antibodies to LC3 and actin. B. L5178Y cells with Tet-On shCasp-8 or 
shLacZ were infected with a lentiviral vector encoding shRNA for ATG7 (shATG7). Seven days after 
infection, the expression of ATG7 was quantified by QRT-PCR. C. L5178Y cells with the indicated 




cells were quantified. D and E. L5178Y cells with Tet-On shCasp-8 or shLacZ were treated together 
with 10 ng/ml Dox and 500 nM wortmanin in DMSO or DMSO only for the periods indicated. Dox 






FIGURE 6. Caspase-8 knockdown cells undergo death through induction of ROS accumulation.  
A and B. L5178Y cells with Tet-On shCasp-8 or shLacZ were treated with 10 ng/ml Dox and either 20 
μM BHA in DMSO or DMSO only for the periods indicated. Numbers of viable and dead cells were 
quantified. Total viable cell number (A) and % of dead cells (B) are indicated. C. Expression of 
shLacZ or shCasp-8 was induced by treatment with Dox for the periods indicated in the presence or 
absence of 20 μM BHA. Amounts of accumulated ROS were measured by flow cytometric analysis 
using DHE.  
 
 
FIGURE 7. RIP1 and RIP3 regulate both apoptotic and non-apoptotic cell death in L5178Y 
cells. 
A. L5178Y cells with Tet-On shCasp-8 or shLacZ were treated with 10 ng/ml Dox and either 50 μM 
Nec-1 in DMSO or DMSO only for the periods indicated. Numbers of viable and dead cells were 
quantified. B. L5178Y cells with Tet-On shCasp-8 were infected with a lentiviral expression vector 
encoding shRNA specific for RIP3 (shRIP3) or shLacZ. After 48 h cultivation, cell lysate was 
analyzed by Western blotting with anti- RIP3 and anti-actin antibodies. C. L5178Y cells with Tet-On 
shCasp-8 and either shLacZ or shRIP3 were treated with 10 ng/ml Dox together with or without 50 
μM Nec-1 for 72 h. Numbers of viable and dead cells were quantified. D. ROS levels in cells 
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 FIGURE S1. Effects of caspase inhibitors on L5178Y cells with or without Tet-On shCasp-8.  
A. L5178Y cells were treated with indicated amounts of z-IETD-fmk in DMSO or DMSO only for 24 
or 48 h. Numbers of viable and dead cells were quantified as described in Fig. 1. B and C. Tet-On 
shCasp-8-expressing L5178Y cells were treated with 10 ng/ml Dox together with indicated amounts 
of z-DEVD-fmk (B) or z-LETD-fmk (C) in DMSO or DMSO only for the periods indicated. z-
DEVD-fmk, z-LETD-fmk and Dox were added every 24 h. Numbers of viable and dead cells were 




FIGURE S2. Effects of exogenously expressing Bcl-xL on staurosporin-induced apoptosis and 
cell death induced by caspase-8 knockdown.  
A. Flag-tagged and untagged Bcl-xL were over-expressed in L5178Y cells with Tet-On shCasp-8 by 
utilizing lentiviral expression vectors at various concentrations (concentration rates: x60 – x10) under 
the control of eEF1A1 (EF) and PGK promoters, respectively. Cell lysate was analyzed by Western 
blotting with antibodies to Bcl-xL, Flag and actin. B and C. L5178Y cells with Tet-On shCasp-8 and 
exogenous Bcl-xL as described in A were cultured with or without 2.5 μM staurosporin (STS) for 3h. 
Numbers of dead cells were quantified as described in Fig. 1 (B). Cell lysate was analyzed for the 
detection of cleaved-caspase-3 by Western blotting with anti-caspase-3 antibody (C). D. shLacZ and 
shCasap-8 expression were induced in exogenous Bcl-xL-expressing cells in A by treatment with 10 
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